Schrodinger (SDGR) Competitors $20.96 0.00 (0.00%) Closing price 03:29 PM EasternExtended Trading$21.04 +0.08 (+0.38%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SDGR vs. TGTX, GRFS, LNTH, TLX, NUVL, AXSM, AKRO, PCVX, ADMA, and KRYSShould you be buying Schrodinger stock or one of its competitors? The main competitors of Schrodinger include TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Schrodinger vs. Its Competitors TG Therapeutics Grifols Lantheus Telix Pharmaceuticals Nuvalent Axsome Therapeutics Akero Therapeutics Vaxcyte ADMA Biologics Krystal Biotech TG Therapeutics (NASDAQ:TGTX) and Schrodinger (NASDAQ:SDGR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends. Which has stronger valuation & earnings, TGTX or SDGR? TG Therapeutics has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$329M17.95$23.38M$0.24155.00Schrodinger$207.54M7.41-$187.12M-$2.63-7.97 Do analysts prefer TGTX or SDGR? TG Therapeutics currently has a consensus price target of $40.80, indicating a potential upside of 9.68%. Schrodinger has a consensus price target of $33.25, indicating a potential upside of 58.64%. Given Schrodinger's higher possible upside, analysts plainly believe Schrodinger is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Schrodinger 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media prefer TGTX or SDGR? In the previous week, TG Therapeutics and TG Therapeutics both had 8 articles in the media. TG Therapeutics' average media sentiment score of 0.73 beat Schrodinger's score of 0.42 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Schrodinger 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more risk and volatility, TGTX or SDGR? TG Therapeutics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Do institutionals & insiders believe in TGTX or SDGR? 58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by company insiders. Comparatively, 8.6% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is TGTX or SDGR more profitable? TG Therapeutics has a net margin of 10.13% compared to Schrodinger's net margin of -83.39%. TG Therapeutics' return on equity of 18.88% beat Schrodinger's return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics10.13% 18.88% 7.05% Schrodinger -83.39%-44.74%-26.29% SummaryTG Therapeutics beats Schrodinger on 13 of the 15 factors compared between the two stocks. Get Schrodinger News Delivered to You Automatically Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SDGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SDGR vs. The Competition Export to ExcelMetricSchrodingerMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.54B$1.98B$5.54B$8.95BDividend YieldN/AN/A5.38%4.08%P/E Ratio-7.9733.7627.3820.03Price / Sales7.4115.98422.31120.16Price / CashN/A54.7436.6357.47Price / Book3.638.708.085.67Net Income-$187.12M-$62.39M$3.16B$248.47M7 Day Performance2.29%1.12%2.12%2.90%1 Month Performance-8.47%3.63%4.43%5.75%1 Year Performance4.28%4.59%35.62%21.36% Schrodinger Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SDGRSchrodinger2.8416 of 5 stars$20.96flat$33.25+58.6%+3.1%$1.54B$207.54M-7.97790News CoverageAnalyst ForecastTGTXTG Therapeutics3.1586 of 5 stars$36.56+1.5%$40.80+11.6%+98.2%$5.80B$329M152.33290GRFSGrifols4.0481 of 5 stars$8.37-4.6%$10.30+23.1%+40.2%$5.75B$7.81B7.1523,822LNTHLantheus4.4562 of 5 stars$80.81+2.0%$130.50+61.5%+1.4%$5.59B$1.53B22.96700TLXTelix PharmaceuticalsN/A$16.39-4.4%$22.00+34.2%N/A$5.54B$516.72M0.00N/ANews CoverageAnalyst ForecastHigh Trading VolumeNUVLNuvalent3.7478 of 5 stars$75.98+1.3%$115.50+52.0%+10.3%$5.46BN/A-17.3140Analyst UpgradeInsider TradeAXSMAxsome Therapeutics4.6544 of 5 stars$101.65+1.0%$172.33+69.5%+31.6%$5.01B$385.69M-17.62380Analyst ForecastAnalyst RevisionAKROAkero Therapeutics3.7421 of 5 stars$54.03-0.3%$82.50+52.7%+131.8%$4.31BN/A-27.7130PCVXVaxcyte1.7733 of 5 stars$33.25+1.2%$136.50+310.5%-56.3%$4.29BN/A-8.33160News CoverageADMAADMA Biologics4.2109 of 5 stars$17.87+0.7%$27.67+54.8%+59.1%$4.27B$426.45M21.02530KRYSKrystal Biotech4.5247 of 5 stars$137.92+4.1%$211.13+53.1%-20.4%$3.99B$290.52M33.15210News CoverageAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies TGTX Competitors GRFS Competitors LNTH Competitors TLX Competitors NUVL Competitors AXSM Competitors AKRO Competitors PCVX Competitors ADMA Competitors KRYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SDGR) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Schrodinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Schrodinger With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SDGR Stock Alerts